A Randomized, Double-Blind, Placebo Controlled, 2-Period, Fixed-Sequence Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Orally Administered MK3207 in Patients During and Between Their Acute Migraine Attacks
Phase of Trial: Phase I
Latest Information Update: 31 Dec 2014
At a glance
- Drugs MK 3207 (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors Merck & Co
- 04 Jan 2008 Status changed from suspended to recruiting.
- 03 Nov 2007 New trial record.